Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Orteronel and Leuprorelin in Prostate Cancer
NCT03211052Phase 2Terminated
- Start
- Feb 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orteronel in prostate cancer (PCa) (2 arms). Primary endpoint: Biochemical Progression Free Survival (PSA) at 3 years. Started Feb 2013; status: terminated.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03211052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211052.